Investigating the role of retrotransposons in hematopoietic neoplasias. This proposal describes a five-year training program for development of an academic career in the genetic basis of hematologic malignancies. I am a physician-scientist, having completed doctoral studies in genetics with a focus on reproductive biology and in vivo tumor modifiers at Baylor College of Medicine as part of the combined M.D., Ph.D. program. I have also completed a residency in clinical pathology/laboratory medicine at Johns Hopkins Hospital where I am currently a clinical hematopathology fellow. I will complete this clinical fellowship in July 2008. I will establish myself as an independent investigator during this award period by developing my postdoctoral research and involving institutional strengths of the Johns Hopkins University School of Medicine. Many outstanding individuals and resources will contribute to a special environment for promoting the success of my research and career development. This effort will specifically involve collaborators within my primary department, the Department of Pathology, and co-mentorship from the Civin laboratory in the Cancer Center and the Boeke laboratory in the High Throughput Biology Center. The career development plan will build on my strong background in classical genetics, adding didactic training and primary research experiences in the forefront of modern genomics. The proposed work will focus on analysis of primary patient samples, which is outside my prior experience and will better position me to perform future studies with translational potential. My research will focus on: (i.) understanding the epigenetics of repetitive element stabilization in hematopoietic malignancies, and (ii.) applying a retrotransposon mapping strategy that I developed during my residency to investigate how these mobile elements contribute to oncogenesis and tumor progression. Insertional mutations caused by LINE repeat transposition are known causes of both heritable disease and somatic mutation in cancer. However, the extent of transposon participation in cancer development is not appreciated because genome-wide mapping strategies have not been available until now. This project is both very innovative and feasible, with potential to add an important dimension to our appreciation of tumor biology. Moreover, if LINE instability contributes meaningfully to cancer recurrence and resistance to therapeutics, this knowledge might be translated to application of antiretroviral therapies in cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08CA134746-03
Application #
7918778
Study Section
Subcommittee G - Education (NCI)
Program Officer
Myrick, Dorkina C
Project Start
2008-08-01
Project End
2013-07-31
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
3
Fiscal Year
2010
Total Cost
$140,130
Indirect Cost
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Rodi?, Nemanja; Sharma, Reema; Sharma, Rajni et al. (2014) Long interspersed element-1 protein expression is a hallmark of many human cancers. Am J Pathol 184:1280-6
Babatz, Timothy D; Burns, Kathleen H (2013) Functional impact of the human mobilome. Curr Opin Genet Dev 23:264-70
Rodi?, Nemanja; Burns, Kathleen H (2013) Long interspersed element-1 (LINE-1): passenger or driver in human neoplasms? PLoS Genet 9:e1003402
Burns, Kathleen H; Boeke, Jef D (2012) Human transposon tectonics. Cell 149:740-52
Huang, Cheng Ran Lisa; Schneider, Anna M; Lu, Yunqi et al. (2010) Mobile interspersed repeats are major structural variants in the human genome. Cell 141:1171-82
Ma, Lang; Buchold, Gregory M; Greenbaum, Michael P et al. (2009) GASZ is essential for male meiosis and suppression of retrotransposon expression in the male germline. PLoS Genet 5:e1000635
Schneider, Anna M; Duffield, Amy S; Symer, David E et al. (2009) Roles of retrotransposons in benign and malignant hematologic disease. Cellscience 6:121-145